Guided Therapeutics director converts note to shares
GUIDED THERAPEUTICS INC director and 10% owner John E. Imhoff reported several equity-related transactions.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
GUIDED THERAPEUTICS INC director and 10% owner John E. Imhoff reported several equity-related transactions. On March 31, 2026, he converted $11,019.18 outstanding under a Convertible Promissory Note into 157,417 shares of common stock at a $0.07 conversion price, while $110,000 of principal remains outstanding and is still convertible under the note’s terms.
On March 26, 2026, he converted 10 shares of Series F preferred stock into 40,000 common shares, and also received 2,157 common shares as payment of accrued dividends on that preferred stock at a $0.2773 conversion price. After these transactions, his direct common stock holdings increased to 21,252,673 shares.
Separately, on March 10, 2026, Imhoff was granted 110,000 stock options for common stock at a $0.29 exercise price. One-fourth vested on March 10, 2026, with the remainder vesting monthly starting June 10, 2026 until fully vested on March 10, 2029.
Insider Trade Summary
157,417 shares exercised/converted
Exercise
6 txns
Insider
Imhoff John E
Role
Director, 10% Owner
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Conversion | Convertible Promissory Note | 157,417 | $0.07 | $11K |
| Conversion | Common Stock | 157,417 | $0.07 | $11K |
| Other | Common Stock | 2,157 | $0.00 | $0.00 |
| Other | Preferred Series F Stock | 10 | $0.00 | $0.00 |
| Other | Common Stock | 40,000 | $0.00 | $0.00 |
| Grant/Award | Stock Options | 110,000 | $0.00 | $0.00 |
Holdings After Transaction:
Stock Options — 110,000 contracts (Direct);
Convertible Promissory Note — 110,000 contracts (Direct);
Preferred Series F Stock — 0 shares (Direct);
Common Stock — 21,252,673 shares (Direct)
Footnotes (4)
- F1. One-fourth of the shares subject to the award vested on March 10, 2026; the remaining shares will vest monthly, starting on June 10, 2026, subject to the reporting person's continued service on each such date, until the award is fully vested on March 10, 2029.
- F2. These shares were issued for payment of accrued dividends on the reporting individual's Series F preferred stock, at a conversion price of $0.2773.
- F3. On March 26, 2026, Mr. Imhoff converted 10 shares of Series F preferred stock into 40,000 shares of common stock. The Series F preferred stock had a stated value of $1,000 and $0.25 conversion price.
- F4. On March 31, 2026, Dr. Imhoff converted $11,019.18 outstanding under a September 25, 2025 Convertible Promissory Note into 157,417 shares of common stock at a conversion price of $0.07 per share. The amount converted consisted of $10,000 of principal and $1,019.18 of accrued interest. Following the reported conversion, $110,000 of principal remains outstanding under the convertible promissory note. Upon the occurrence of an event of default, the remaining balance is convertible into common stock at a variable conversion price determined in accordance with the terms of the note.
Key Figures
Note conversion amount: $11,019.18
Shares from note conversion: 157,417 shares
Remaining note principal: $110,000
+5 more
8 metrics
Note conversion amount
$11,019.18
Converted under Convertible Promissory Note on March 31, 2026
Shares from note conversion
157,417 shares
Common stock at $0.07 conversion price on March 31, 2026
Remaining note principal
$110,000
Principal still outstanding under the Convertible Promissory Note
Preferred conversion shares
40,000 shares
Common stock from 10 Series F preferred shares on March 26, 2026
Dividend payment shares
2,157 shares
Common stock issued for accrued dividends at $0.2773 per share
Common shares after transactions
21,252,673 shares
Direct common stock holdings following reported March 2026 actions
Stock options granted
110,000 options
Options for common stock at $0.29 exercise price, granted March 10, 2026
Option vesting end date
March 10, 2029
Award fully vests by this date, with monthly vesting starting June 10, 2026
Key Terms
Convertible Promissory Note, Series F preferred stock, conversion price, stock options, +1 more
5 terms
Convertible Promissory Note financial
"converted $11,019.18 outstanding under a September 25, 2025 Convertible Promissory Note"
A convertible promissory note is a loan a company takes now that can later be turned into shares instead of being repaid in cash. Think of it as lending money with the option to accept ownership in the business down the road; that matters to investors because it affects who gets paid first, how much ownership existing shareholders keep, and the company’s future valuation and cash needs. Terms such as conversion price, interest and maturity determine the financial impact.
Series F preferred stock financial
"converted 10 shares of Series F preferred stock into 40,000 shares of common stock"
Series F preferred stock is a class of company shares that gives holders priority over common shareholders for dividend payments and for getting money back if the company is sold or liquidated, much like a ticket that moves you to the front of the line. These shares often carry a fixed dividend and special rights—sometimes including conversion into common stock—so investors consider them when weighing income, downside protection and potential ownership dilution.
conversion price financial
"at a conversion price of $0.07 per share"
The conversion price is the fixed price at which a convertible security, like a bond or preferred stock, can be exchanged for shares of common stock. It acts like a set rate that determines how many shares an investor can receive if they choose to convert their investment. This helps investors understand the value and potential benefits of converting their securities into company shares.
stock options financial
"Imhoff was granted 110,000 stock options for common stock at a $0.29 exercise price"
Stock options are agreements that give a person the right to buy or sell a company's stock at a specific price within a certain time frame. They are often used as a reward or incentive, similar to a coupon that can be used later if the stock price rises, allowing the holder to make a profit.
accrued dividends financial
"shares were issued for payment of accrued dividends on the reporting individual's Series F preferred stock"
Accrued dividends are payments a company owes to shareholders that have been earned or officially declared but not yet paid; think of them as an IOU the company has for past dividend obligations. They matter to investors because they represent a near-term claim on a company’s cash, affect the company’s reported liabilities and value, and can be especially important when assessing income reliability or priority in a payout situation.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did GTHP director John E. Imhoff do with his convertible promissory note?
He converted $11,019.18 under a September 25, 2025 Convertible Promissory Note into 157,417 common shares at $0.07 per share, while $110,000 of principal remains outstanding and continues to be convertible under the note’s terms.
What stock option grant did Imhoff receive from Guided Therapeutics (GTHP)?
On March 10, 2026, Imhoff received 110,000 stock options for Guided Therapeutics common stock with a $0.29 exercise price. One-fourth vested immediately, and the remaining options vest monthly from June 10, 2026 until full vesting on March 10, 2029.
How was Guided Therapeutics (GTHP) Series F preferred stock converted by Imhoff?
On March 26, 2026, Imhoff converted 10 shares of Series F preferred stock into 40,000 common shares at a stated value of $1,000 per preferred share and a $0.25 conversion price, eliminating his remaining Series F preferred holdings in this filing.
AI-generated analysis. How Rhea-AI works. Not financial advice.
